At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Closed 11-22 16:00:00 EST
388.42
+14.43
+3.86%
High389.95Low369.50Vol22.92M
Open374.11D1 Closing373.99Amplitude5.47%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O153.59MT/O Rate--Tradable Shares0.00
P/B2.045828ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Motley Fool  ·  11-22 20:30
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024?
Insider Monkey  ·  11-22 06:15
Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024?
Caribou Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  11-21 05:00
Caribou Biosciences to Participate in Upcoming Investor Conferences
Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment
THOMSON REUTERS  ·  11-20 22:33
Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
Zacks  ·  11-20 22:21
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment
Reuters  ·  11-20 18:55
BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment
Sangamo Therapeutics Shares up 12.2% Premarket After FDA Clears Application to Start Trial for Pain Treatment
THOMSON REUTERS  ·  11-20 18:49
Sangamo Therapeutics Shares up 12.2% Premarket After FDA Clears Application to Start Trial for Pain Treatment
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
TIPRANKS  ·  11-20 09:15
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now
Insider Monkey  ·  11-20 08:03
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now
BRIEF-Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503
Reuters  ·  11-20 06:14
BRIEF-Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503
Sangamo stock climbs 12% post-market on FDA update for ST-503
seekingalpha  ·  11-20 05:51
Sangamo stock climbs 12% post-market on FDA update for ST-503
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment
Dow Jones  ·  11-20 05:41
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment
Sangamo gets FDA clearance of IND application for ST-503 in iSFN
TIPRANKS  ·  11-20 05:20
Sangamo gets FDA clearance of IND application for ST-503 in iSFN
Sangamo up 11% at $2.17 on FDA clearing IND for ST-503
TIPRANKS  ·  11-20 05:20
Sangamo up 11% at $2.17 on FDA clearing IND for ST-503
Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
THOMSON REUTERS  ·  11-20 05:15
Sangamo Therapeutics Announces U.S. FDA Clearance of Ind Application for St-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025
THOMSON REUTERS  ·  11-20 05:15
Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Business Wire  ·  11-20 05:15
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Intellia Therapeutics Announces Promising CRISPR Therapy Results
TipRanks  ·  11-19
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)
TIPRANKS  ·  11-19
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Bluebird Bio (BLUE) and Spruce Biosciences (SPRB)
TIPRANKS  ·  11-19
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Bluebird Bio (BLUE) and Spruce Biosciences (SPRB)

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--